(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of Pharmaceuticals National Pharmaceutical Pricing Authority

New Delhi, 26 February, 2019

ORDER

S. O. 1030(E) In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

<u>Table</u>

| Sl. | Name of the | Strength | Unit | Manufacturer & | Retail |
|-----|------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|----------|-----------------------------------------------------------------------------|----------------|
| No. | Formulation / Brand Name | | | Marketing Company | Price (Rs.) |
| (1) | (2) | (3) | (4) | (5) | (6) |
| 1. | Escitalopram + Clonazepam Tablet (Andefre- LS) | Each film coated tablet contains: Escitalopram Oxalate IP eq. to Escitalopram 5mg, Clonazepam IP 0.25mg | 1 Tablet | M/s Pure & Cure Healthcare Pvt. Ltd. / M/s Neomac Pharmaceuticals Pvt. Ltd. | 5.88 |
| 2. | Paracetamol + Aceclofenac Tablet | Each uncoated tablet contains: Paracetamol IP 325mg, Aceclofenac IP 100mg. | 1 Tablet | M/s Caplet India Private Limited | 3.35 |
| 3. | Misoprostol Tablet | Each uncoated tablets contains: Misoprostol 25mcg | 1 Tablet | M/s Acme Formulation Pvt. Ltd. / M/s Zydus Healthcare Limited | 4.37 |
| 4. | Mefenamic Acid + Paracetamol Tablet | Each uncoated tablets contains: Mefenamic Acid IP 500mg, Paracetamol IP 325mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Abbott Healthcare Pvt. Ltd. | 2.76 |
| 5. | Trastuzumab Injection | Each Lyophilized Vial contains: Trastuzumab 150mg | 1 Vial | M/s Cadila Healthcare Limited / M/s Glenmark Pharmaceuticals Limited | 18400.89 |
| 6. | Cilnidipine + Telmisartan + Chlorthalidone Tablet | Each film coated tablet contains: Cilnidipine IP 10mg, Telmisartan IP 40mg Chlorthalidone IP 6.25mg | 1 Tablet | M/s Windlas Biotech Pvt. Ltd. /M/s Emcure Pharmaceuticals Limited | 10.43 |
| 7. | Metformin + Gliclazide Tablet | Each uncoated bilayered tablet contains: Metformin Hydrochloride IP 500mg (in extended release | 1 Tablet | M/s Anphar Organics Pvt. Ltd. / M/s Lupin Limited | 6.31 |

| | | form) Gliclazide IP 80mg (as modified release form) | | | |
|-----|--------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|---------------------------------------------------------------------------|-------|
| 8. | Metformin + Gliclazide Tablet | Each uncoated bilayered tablet contains: Metformin Hydrochloride IP 500mg (in extended release form) Gliclazide IP 60mg (as modified release form) | 1 Tablet | M/s Anphar Organics Pvt. Ltd. / M/s Lupin Limited | 8.64 |
| 9. | Telmisartan + Metoprolol Tablet (TELMELIFE – M25) | Each film coated bilayered tablet contains: Telmisartan IP 40mg, Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate (as extended release form) 25mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Neomac Pharmaceuticals (P) Ltd. | 9.43 |
| 10. | Telmisartan + Metoprolol Tablet (TELMELIFE – M50) | Each film coated bilayered tablet contains: Telmisartan IP 40mg, Metoprolol Succinate IP 47.5mg eq. to Metoprolol Tartrate (as extended release form) 50mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Neomac Pharmaceuticals (P) Ltd. | 11.72 |
| 11. | Propranolol + Flunarizine Capsule | Each hard gelatine capsule contains: Propranolol Hydrochloride IP 40mg (as SR pellets), Flunarizine Dihydrochloride BP eq. to Flunarizine 5mg (as pellets) | 1 Capsule | M/s Innova Captab Ltd. / M/s Cipla Limited | 6.72 |
| 12. | Propranolol + Flunarizine Capsule | Each hard gelatine capsule contains: Propranolol Hydrochloride IP 40mg (as SR pellets), Flunarizine Dihydrochloride BP eq. to Flunarizine 10mg (as pellets) | 1 Capsule | M/s Innova Captab Ltd. / M/s Cipla Limited | 9.20 |
| 13. | Levonorgestrel Tablet | Each uncoated tablet contains: Levonorgestrel IP 1.5mg | 1 Tablet | M/s Mylan Laboratories Limited / M/s Mylan Pharmaceutical Private Limited | 92.80 |
| 14. | Formoterol + Budesonide Respirator suspension (Budetrol 0.5) | Each ml respule contains: Formoterol Fumarate Dihydrate IP eq. to Formoterol Fumarate 20mcg, Budesonide IP 0.5mg | Each 2 ML Pack | M/s Axa Parenterals Ltd. / M/s Macleods Pharmaceutical Limited | 36.04 |
| 15. | Formoterol + Budesonide Respirator suspension (Budetrol 1) | Each ml respule contains: Formoterol Fumarate Dihydrate IP eq. to Formoterol Fumarate 20mcg, Budesonide IP 1mg | Each 2 ML Pack | M/s Axa Parenterals Ltd. / M/s Macleods Pharmaceutical Limited | 42.12 |

| 16. | Metformin + Glimepiride Tablet (Geminor 0.5) | Each uncoated bilayered tablet contains: Metformin Hydrochloride IP 500mg, (as Prolonged release form) Glimepiride IP 0.5mg | 1 Tablet | M/s Macleods Pharmaceutical Limited | 3.57 |
|-----|----------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|-------------------------------------|-------------------------------------------------------------------|-------|
| 17. | Clobazam Suspension | Each ml suspension contains: Clobazam IP 2.5mg | 1 ML | M/s Intas Pharmaceutical Limited | 2.54 |
| 18. | Diclofenac + Chlorzoxazone Tablet (MYOSPAS-F) | Each film coated tablet contains: Diclofenac Potassium BP 50mg Chlorzoxazone USP 500mg | 1 Tablet | M/s G. S. Pharmbutor Pvt. Ltd. /M/s Win- Medicare Pvt. Ltd. | 9.28 |
| 19. | Clonazepam Orally disintegrating Strips (Melzap ODS 0.5) | Each Orally disintegrating Strips contains: Clonazepam IP 0.5mg | 1 Orally disintegrating Strip | M/s ZIM Laboratories Limited / M/s Alkem Laboratories Ltd. | 5.33 |
| 20. | Clonazepam Orally disintegrating Strips (Melzap ODS 1) | Each Orally disintegrating Strips contains: Clonazepam IP 1mg | 1 Orally disintegrating Strip | M/s ZIM Laboratories Limited / M/s Alkem Laboratories Ltd. | 7.25 |
| 21. | Clonazepam Orally disintegrating Strips (Melzap ODS 2) | Each Orally disintegrating Strips contains: Clonazepam IP 2mg | 1 Orally disintegrating Strip | M/s ZIM Laboratories Limited / M/s Alkem Laboratories Ltd. | 13.05 |

Note:

- (a) The manufacturer of above mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
- (b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
- (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.

- (f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
- (g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/195/63/2019/F

F. No. 8(63)/2019/D.P./NPPA-Div.-II

(Prasenjit Das) Assistant Director